cemiplimab + docetaxel

Cemiplimab + docetaxel is a combination regimen being investigated primarily for advanced non-small cell lung cancer (NSCLC), often in combination with ramucirumab, for patients who have experienced progression after prior platinum-based chemotherapy and immunotherapy. Cemiplimab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), acting as a checkpoint inhibitor to enhance the body's immune response against tumors. Docetaxel is a cytotoxic chemotherapy drug in the taxane class that inhibits microtubule depolymerization, thereby arresting cancer cell division and leading to apoptosis[1][2][3][4][7]. This combination, particularly when paired with ramucirumab, is being tested to improve survival and response rates in resistant NSCLC, with ongoing phase II/III studies.

Other names

CemiplimabDocetaxel